glp 1 new indications GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits GLP1 medicines now address weight

Twenty grams/day of Immunocal significantly enhanced muscular performance and lymphocyte GSH in a group of 20 young adults

According to the company: ColonBroom describes this extract as providing potent antioxidants while promoting cardiovascular health, balanced blood sugar, and improved insulin response

This results in lower caloric intake and, over time, significant weight loss

Start your intake Major Pharmaceutical Companies Producing GLP-1 Medications Novo Nordisk, a Danish multinational, holds the original patent and manufactures brand-name semaglutide (Ozempic, Wegovy) and tirzepatide is produced by Eli Lilly (Mounjaro, Zepbound)

A summary of the quality assessment for the included studies can be found in Supplementary Table 2

Cardiovascular benefits